

*Hong Kong Exchanges and Clearing Limited and The Stock Exchange of Hong Kong Limited take no responsibility for the contents of this announcement, make no representation as to its accuracy or completeness and expressly disclaim any liability whatsoever for any loss howsoever arising from or in reliance upon the whole or any part of the contents of this announcement.*



**COL Capital Limited**

*(Incorporated in Bermuda with limited liability)*

**(Stock Code: 383)**

## **APPOINTMENT OF NON-EXECUTIVE DIRECTORS**

The Board is pleased to announce that Dr. Lim Cheok Peng and Dr. Jonathan Weiyan Seah have been appointed as non-executive directors of the Company with effect from 26 October 2015.

The board of directors (the “**Board**”) of COL Capital Limited (“**Company**”) is pleased to announce that Dr. Lim Cheok Peng (“**Dr. Lim**”) and Dr. Jonathan Weiyan Seah (“**Dr. Seah**”) have been appointed as non-executive directors of the Company with effect from 26 October 2015.

### **Dr. Lim Cheok Peng**

Dr. Lim, aged 68, was appointed as a non-executive director of the Company on 26 October 2015.

Dr. Lim has over 25 years of international experience in the healthcare sector. He has extensive experience both as a medical practitioner and in managing hospital businesses. He is a chairman of Ophir Ventures Sdn Bhd and previous to this was a senior advisor to the board of directors at IHH Healthcare Berhad (“**IHH**”), a company which is listed on the Kuala Lumpur Stock Exchange and has a secondary listing on the Singapore Exchange and a managing director/executive director of IHH during the periods of 5 April 2012 to 31 December 2013 and 1 May 2011 to 4 April 2012 respectively. Prior to that, Dr. Lim was a vice chairman/executive vice chairman/managing director of Parkway Holdings Limited, a company which was listed on the Singapore Exchange, during the periods of 1 April 2011 to 26 May 2011, 24 April 2009 to 31 March 2011 and 7 June 2000 to 23 April 2009 respectively. Dr. Lim is also the president of IXL Partners since October 2015.

Dr. Lim graduated from the University of Singapore in 1972 with a bachelor of medicine and bachelor of surgery. In 1976, he obtained a master in medicine (internal medicine) from the University of Singapore. Dr. Lim was presented with the Singapore Medical Association Merit Award in 2013 for his significant contributions to the medical profession and the social service to the community in Singapore.

Dr. Lim has entered into a letter of appointment with the Company and the term of his service shall continue for a period of two years and shall be renewed automatically for successive two-year term or until terminated in accordance with the said letter of appointment. His appointment is also subject to the relevant provisions of retirement and re-election at the annual general meetings of the Company. Dr. Lim will hold office until the next following annual general meeting of the Company and will be eligible for re-election at that meeting in accordance with the Bye-laws or any other applicable laws whereby he shall vacate his office. Dr. Lim will be entitled to receive HK\$180,000 per annum as director's remuneration which is determined by reference to the market salary range for the position.

Save as disclosed above and that Dr. Lim is beneficially interested in 300,000,000 shares in long position in the Company ("**Shares**") under an option agreement dated 26 October 2015 entered into between Dr. Lim and IXL Ventures L.P. acting by its general partner, IXL Partners, as at the date of this announcement, (i) Dr. Lim does not have any relationship with any directors, senior management, substantial or controlling shareholders of the Company; (ii) he does not have any interest in the Shares of the Company within the meaning of Part XV of the Securities and Futures Ordinance (Chapter 571 of the Laws of Hong Kong); (iii) he does not hold any other directorships in public companies the securities of which are listed on any securities market in Hong Kong or overseas in the last three years; and (iv) he does not hold other positions with the Company or its subsidiaries.

#### **Dr. Jonathan Weiyan Seah**

Dr. Seah, aged 45, was appointed as a non-executive director of the Company on 26 October 2015.

Dr. Seah has over 20 years of experience in clinical medicine, investment banking, private equity, and general management in the USA, China, and Southeast Asia.

Dr. Seah is the managing director of IXL Ventures L.P., IXL Partners, IXL Fund, IXL Capital, and Living Ventures Holdings Limited. Dr. Seah was previously the founding chief executive officer of ParkwayHealth's China Division, an operator of international-quality medical centers in China. He was also previously a director of First Steamship Co., Ltd from 1 August 2012 to 5 February 2014 and is a director of Grand Ocean Retail Group Ltd since 30 August 2011, both of which are listed on the Taiwan Stock Exchange. Prior to this, Dr. Seah was a corporate finance investment banker with Merrill Lynch Pierce Fenner & Smith, Inc. in California, USA. Before attending business school, Dr. Seah was a medical doctor at the National University Hospital, Tan Tock Seng Hospital, and Raffles Medical Group in Singapore.

Dr. Seah was a director from 23 April 2010 to 12 June 2012 and the chairman from 8 May 2013 to 15 October 2013 of 連雲港嘉泰建設工程有限公司 (Lianyungang Jiatai Construction Co., Ltd.\*) ("**Jiatai Construction**"), a direct non wholly-owned subsidiary of the Company. He was also a director from 7 May 2010 to 20 June 2012, and the chairman from 7 August 2012 to 15 October 2013 of 同仁醫療產業集團有限公司 (Tongren Healthcare Industry Group Company Limited\*), an indirect non wholly-owned subsidiary of Jiatai Construction.

\* *for identification purpose only*

Dr. Seah holds an MBA from Harvard Business School and a bachelor's degree in medicine from the Royal College of Surgeons in Ireland.

Dr. Seah has entered into a letter of appointment with the Company and the term of his service shall continue for a period of two years and shall be renewed automatically for a successive two-year term or until terminated in accordance with the said letter of appointment. His appointment is also subject to the relevant provisions of retirement and re-election at the annual general meetings of the Company. Dr. Seah will hold office until the next following annual general meeting of the Company and will be eligible for re-election at that meeting in accordance with the Bye-laws or any other applicable laws whereby he shall vacate his office. Dr. Seah will be entitled to receive HK\$180,000 per annum as director's remuneration which is determined by reference to the market salary range for the position.

Save as disclosed above and that Dr. Seah is deemed to have a corporate interest in 2,000,000,000 Shares in long position and 300,000,000 Shares in short position in the Company under option agreements dated 15 October 2015 entered into between Vigor Online Offshore Limited (the controlling shareholder of the Company) and IXL Ventures L.P. acting by its general partner, IXL Partner (a company in which Dr. Seah maintains 100% beneficial interest) and dated 26 October 2015 entered into between Dr. Lim and IXL Ventures L.P. acting by its general partner, IXL Partners respectively, as at the date of this announcement, (i) Dr. Seah does not have any relationship with any directors, senior management, substantial or controlling shareholders of the Company; (ii) he does not have any interest in the Shares of the Company within the meaning of Part XV of the Securities and Futures Ordinance (Chapter 571 of the Laws of Hong Kong); (iii) he does not hold any other directorships in public companies the securities of which are listed on any securities market in Hong Kong or overseas in the last three years; and (iv) he does not hold other positions with the Company or its subsidiaries.

Save as disclosed above, there is no information in relation to the appointment of Dr. Lim and Dr. Seah that is required to be disclosed pursuant to Rule 13.51(2)(h) to 13.51(2)(v) of the Rules Governing the Listing of Securities on The Hong Kong of Stock Exchange Limited and there is no other matter that needs to be brought to the attention of holders of securities of the Company.

The Board would like to extend a warm welcome to Dr. Lim and Dr. Seah in joining the Board.

By Order of the Board  
**COL Capital Limited**  
**Chong Sok Un**  
*Chairman*

Hong Kong, 26 October 2015

*As at the date of this announcement, the Board comprises Ms. Chong Sok Un (Chairman), Dato' Wong Peng Chong and Mr. Kong Muk Yin as Executive Directors; Dr. Lim Cheok Peng and Dr. Jonathan Weiyen Seah as Non-Executive Directors; and Mr. Lau Siu Ki, Mr. Ma Wah Yan and Mr. Zhang Jian as Independent Non-Executive Directors.*